Securing America’s Pharmaceutical Supply Chain Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jun 1, 2021)
Securing America's Pharmaceutical Supply Chain Act
This bill allows an executive agency to purchase a drug approved or licensed by the Food and Drug Administration only if the drug is over 50% sourced, manufactured, and assembled in the United States.
This requirement may be waived (1) if the drug is not available in sufficient quantity or quality as over 50% sourced, manufactured, and assembled in the United States; or (2) during an emergency.
The U.S. Trade Representative (USTR) shall modify U.S. product coverage under all free trade agreements and the World Trade Organization Agreement on Government Procurement to exclude coverage of essential medicines and medical countermeasures. Subsequent to such modifications, the USTR shall make any necessary corresponding modifications of existing waivers and notify the Office of Management and Budget.
What just happenedJun 1, 2021
Referred to the Subcommittee on Trade.
Who’s behind it
- Introduced in HouseJun 1, 2021
- Jun 1, 2021Committee
Referred to the Subcommittee on Trade.
Trade Subcommittee - Jun 1, 2021IntroReferralH11100
Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Jun 1, 2021IntroReferralH11100
Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oversight and Accountability Committee - Jun 1, 2021IntroReferralIntro-H
Introduced in House
- Jun 1, 2021IntroReferral1000
Introduced in House